BioPharmSignal logoBioPharmSignal

Biotech News

Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (FENC)Fennec Pharmaceuticals Inc.Earnings

~ Delivered Record Annual Revenue with Full-Year Net PEDMARK ® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75% Growth Over Q4 2024 Net Product Sales ~ ~ Executed on 2025 Clinical Data Strategy to Expand

Related news

FENCFennec Pharmaceuticals Inc.2026-08-11 11:01 EST

Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

FENCFennec Pharmaceuticals Inc.2026-08-05 11:01 EST

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

IMCRImmunocore Holdings plc2026-08-06 11:00 EST

Immunocore reports second quarter financial results and provides a business update

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Fennec Pharmaceuticals Inc.

Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy. Pediatric Commercial Foundation PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through...

Recent company news

FENCFennec Pharmaceuticals Inc.2026-08-11 11:01 EST

Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

FENCFennec Pharmaceuticals Inc.2026-08-05 11:01 EST

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

FENCFennec Pharmaceuticals Inc.2026-06-15 10:00 EST

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

FENCFennec Pharmaceuticals Inc.2026-06-10 20:30 EST

Fennec Announces Results of Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-05-21 22:01 EST

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

Stock data

Close
11.29 USD
Market cap
346.68M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States